title: Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor.
abstract: OBJECTIVE
  To evaluate the efficacy of the FAEV regimen (floxuridine, actinomycin D, etoposide, vincristine) in the treatment of high-risk, drug-resistant gestational trophoblastic tumor (GTT).
  
  
  METHODS
  From October 2001 to May 2004, 11 cases of high-risk, drug-resistant GTT were treated with the FAEV regimen. All cases were referred to Peking Union Medical College Hospital because of previous failure of chemotherapy. The patients' ages ranged from 21 to 60 (median, 32) years. The International Federation of Gynecologists and Obstetricians score was 7-13 (median, 9). All cases were followed for 15-42 months after FAEV treatment.
  
  
  RESULTS
  Seven cases (63.6%, 7 of 11) were cured by the FAEV regimen. The median course number for serum human chorionic gonadotropin reaching a normal level was 3. Four cases (36%, 4 of 11) showed drug resistance to the FAEV regimen. The major side effect of FAEV regimen is myelosuppression. Granulocyte colony-stimulating factor support was needed after 98.4% (63 of 64) of the courses.
  
  
  CONCLUSIONS
  For high-risk, drug-resistant GTT cases, FAEV regimen could be an effective treatment.
authors.affiliation: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, People's Republic of China. wanxr@pumch.cn
authors.forename: Xirun
authors.initials: X
authors.lastname: Wan
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiang
authors.forename: Xiuyu
authors.initials: X
authors.lastname: Yang
authors.forename: Yu
authors.initials: Y
authors.lastname: Wu
authors.forename: Ning
authors.initials: N
authors.lastname: Liu
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Ruofan
authors.initials: R
authors.lastname: Dong
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D006063:Chorionic Gonadotropin / Q000097:blood; D003609:Dactinomycin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005500:Follow-Up Studies; D031901:Gestational Trophoblastic Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D006063:Chorionic Gonadotropin; D005467:Floxuridine; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide